ISSN: 1301-2193 E-ISSN: 1308-9846
  • Turkish Journal of
    Endocrinology and Metabolism


The relation between hypertension, insulin resistance and hyperinsulinemia is well known. In untreated essential hypertensive patients, fasting and postprandial insulin levels were higher than the results in normotensive controls and when adjusted for body mass index, a direct relationship was found between plasma insulin levels and blood pressure (1,2,3). According to large prospective studies conducted in several populations, the risk of developing type 2 diabetes is greater in patients with essential hypertension compared to non-hypertensive individuals (4).

The renin-angiotensin system (RAS), which plays a key role in the regulation of blood pressure, is known to have an effect on the development of insulin resistance and diabetes. In the same manner, insulin resistance also has effects on the RAS tissue. In insulin resistance, by means of postranscriptional mechanisms, angiotensin receptor 1’s (AT1) upregulation in tissues and an increase in activity and production of angiotensin II (AT II) production occur (5). There is evidence that AT II inhibits insulin-induced vasodilatation and glucose transport (6,7). Inhibition of RAS may reduce insulin resistance by improving blood flow in muscle tissues (8), by reducing sympathetic activity (9), by making changes in the levels of serum ions (10), by regulating the insulin signaling pathway independently of vasodilation and thus by increasing peripheral glucose utilization (11) and with the effects of adipokines with fatty tissue (12) . At the same time, it is thought that RAS inhibition has positive contributions to insulin secretion by its corrective effect on the ionic balance of potassium and magnesium and by improving microcirculation of pancreatic beta-cells (13).

RAS inhibition drugs such as angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) significantly lower insulin resistance and have antidiabetic effects. Because of their positive metabolic effects, they are popular agents in terms of development of diabetes. ACEI’s and ARB’s protective effects on the inhibition of the RAS have been found to be similar, the conducted meta-analyses calculated that RAS inhibition decrease approximately 22% of the relative risk of developing type 2 diabetes by using this group of drugs (14).

Recently, antidiabetic effects of ARBs were found to be seen as partial PPAR-gamma agonism (peroxisome proliferator-activated receptor-gamma) (15). PPAR-gamma activation provides differantiation of preadipocytes to mature adipocytes in fatty tissue, and it provides insulin sensitivity enhancing effect in adipose tissue. Again, the secretion of cytokines which have negative effect on insulin resistance, such as free fatty acids, tumor necrosis factor alpha, interleukin-6 and resistin, decrease and insulin-sensitizing adiponectin secretion increases (16). At At1r removed cell models, this PPAR-gamma activity was found to be maintained, thus it was concluded that inhibition of this activity was independent of RAS (15). Among ARBs, only telmisartan has a PPAR-gamma-stimulating effect at therapeutic concentrations, where high doses of irbesartan (partially) and candesartan (a little less) have similar activity (17). No PPAR-gamma activity was observed at any concentration of the other ARBs or losartan (17,18).

In our study, we aimed to compare the effects of telmisartan and losartan on insulin resistance in patients with treated type 2 diabetes. In this way, we aimed to investigate if there is significant advantage of telmisartan, a dual-acting drug which has the RAS inhibition and partial PPAR-gamma activity at therapeutic doses, over classical ARBs which, do not have known PPAR-gamma activity in clinical practice.

Materials and Methods

Patient Selection

This study includes 20 patients who applied to Başkent University Adana Teaching and Research Hospital, Endocrinology and Metabolic Diseases. Patients were newly diagnosed with type 2 diabetes, they were medically untreated and had mild to moderate hypertension. All type 2 diabetes diagnoses were based on The American Diabetes Association Guide published in 2004 (19). Patients were diagnosed with mild to moderate hypertension if they had stage 1 hypertension according to Joint National Committee VII criterias (20). Smokers, patients with chronic alcoholism problem, uncontrolled hypertensive patients with arterial blood pressure averaged 140/90 mm / Hg in last three weeks, type 1 diabetic patients, poorly controlled diabetics with glucosyl hemoglobin (HbA1c)> 8%, pregnant women, patients with single kidney or malignancy, patients with any endocrinological chronic disease, liver or kidney failure and patients over the age of 65 were excluded from the study. After approval of the Başkent University Faculty of Medicine central ethics committee with project number KA-05/256, the patients included in the study read and approved volunteers’ information sheet.

Preparatory Period

Insulin secretogog monotherapy (sulfonylurea or meglitinide) was started for diabetes patients enrolled in the study group and patients were divided into two groups based on their antihypertensive treatment. Group 1 patients (n=10; 5 females, 5 males) was started losartan 50 mg / day and group 2 patients (n=10; 3 females, 7 males) was started telmisartan 80 mg / day. Both groups were advised with proper nutrition diets. Blood glucose and blood pressure regulation was provided with monthly visits.

Study Design

At the end of three months of treatment, patients received standard-carbohydrate diet for 3 days and after 12 hours fasting; their arterial blood pressures, waist circumferences and body weights were measured; body-mass index (BMI) was calculated as kg/m2. Serum potassium, creatinine, glucosyl hemoglobin (HbA1c) levels, fasting plasma glucose levels and basal insulin were measured from patients’ venous blood samples. HOMA-IR values were calculated with the {Fasting Glucose (mmol / l) x fasting insulin (mU/mL)} / 22.5 formula. A portion of the venous blood plasma was stored to analyze adiponectin levels later. For each patient, hyperinsulinemic euglycemic clamp test (HECT) was applied based on the method described by de Fronzo and calculated M values were recorded (21).

Lag period: Then both groups’ anti-hypertensive treatments (telmisartan and losartan) were stopped for a period of two weeks (wash-out period). In this process, patients’ daily blood pressure monitoring were collected against the risk of hypertensive emergencies and none of the patients had an increase at their blood pressure, which might have required their removal from the study.

Follow-up period: After two weeks of drug-free period, group 1 (the group who started with losartan treatment) was given 80 mg/day telmisartan and Group 2 (the group who started with telmisartan) was given 50 mg/day losartan. Patients were recommended not to make a significant change in their dietary compliance and physical activity, and their blood pressure and blood sugar were followed through monthly visits. None of the patients required a change in their oral antidiabetic or antihypertensive medication dose.

End of study

At the end of third month, all patients’ biochemical and anthropometric measurements were re-taken, blood samples were taken for serum adiponectin levels and M values were recorded by performing HECT.

Height and body weight of patients were measured in a standard scale. Blood pressure was recorded by calculating the average of three measurements taken with standard arm sleeve sphygmomanometer after 5 minutes of resting. Plasma glucose was measured with enzymatic colorimetric method (glucose oxidase method), creatinine was measured with kinetic colorimetric method; and potassium levels were measured with ion selective electrode method in biochemistry analyzer (Roche Modular DP). Plasma fasting insulin levels were measured with microparticle enzyme immunassey method (Axsym Abbott Diagnostics Division), and adiponectin levels were measured with enzyme linked immunosorbent assey (ELISA) method (BIOVENDOR Human adiponectin Elise, Tecan Sunrise).

SPSS 11.0 for Windows was used for statistical evaluation. Both groups’ patient characteristics and the parameters’ mean values were determined by cross-tabs. Intergroup comparisons were performed by using independent samples t-test. In each group, the change in patients’ own characteristics and parameters at the beginning and at the end were compared with paired samples t-test. For statistical significance p value was considered to be smaller than 0.05.


Initially, 20 patients were included in the study, (2 groups including 10 patients). One patient from the first and 2 patients from the second group were excluded from the study for not attending visits regularly. Nine patients (4 female, 5 male) from group 1 and eight patients (one female, 7 male) from group 2, a total of 17 patients, completed the study. The average age of the patients was 51.2 ± 6.4 years for group 1; and 44.6 ± 6.2 years for group 2. Characteristics of the patients at the beginning and at the end are given in Tables 1 and 2.

1-    Body weight and BMI: At the beginning of the study there was no significant difference between two groups in terms of average body weight and BMI (p=0.39). At the end of the study, there was a significant decrease in group 1 patients’ body weights and BMI in Group 1 (p=0.034 and p=0.023). At the end of the study, Group 2 patients mean body weight and BMI did not change significantly compared to the beginning (p=0.27 and p=0.34).

2-    Blood pressure: At the beginning of the study, both groups had similar systolic blood pressure (SBP) values (p=0.67). In Group 2 patients, the mean diastolic blood pressure (DBP) levels were significantly lower compared to Group 1 patients DBP (p=0.043). At the end of the study, in both groups, there was no statistically significant change in terms of SBP and DBP compared to the initial measurements (Table 1 and 2).

3-    Fasting Plasma Glucose (FPG) and glycosylated hemoglobin (HbA1c) levels: At the beginning of the study, in both groups, starting FPG levels did not differ statistically (p=0.49). HbA1c levels were significantly lower in Group 2 (p=0.032). At the end of the study, in both groups, mean FPG and HbA1c levels did not differ significantly compared to the initial measurements (Tables 1 and 2).

4-    Adiponectin: At the beginning of the study, there was no statistically significant difference between two groups in terms of average adiponectin levels (p=0.38). At the end of the study, there was no statistically significant difference at the adiponectin levels compared to initial measurements (p=0.27 and p=0.087).

5-    Insulin, HOMA-IR, and M value: At the beginning of the study, there was no statistically significant difference between two groups in terms of fasting plasma insulin, HOMA-IR and M values calculated with HECT (p=0.072, p=0.39 and p=0, 48).

At the end of the study, in Group 1 patients, there was no significant change compared to initial values in terms of median fasting plasma insulin levels, HOMA-IR and M values calculated by HECT (Table 1).

In Group 2 patients, there was a slight but statistically insignificant decrease compared to the initial values in terms of fasting insulin level and HOMA-IR values (Table 2). However, in Group 2, there was a statistically significant increase in M values calculated by HECT compared to the initial values (p=0.028).

6-    Serum creatinine and potassium levels: During follow-up, none of the patients enrolled in the study had any elevation in serum creatinine or potassium levels that would have changed the treatment.


In our study, the group switched from losartan to telmisartan (Group 2) showed more improvement in insulin sensitivity determined by HECT than the group switched from telmisartan to losartan (Group 1). In contrast, in the group that switched to telmisartan, significantly decreased body weight values were recorded compared to the other group. In both groups, there were no difference between blood pressure, fasting plasma glucose, basal insulin levels, HOMA-IR values and adiponectin levels.

In several experimental and clinical studies, telmisartan and losartan have been shown to increase insulin sensitivity, reduce the occurrence of diabetes and lower fasting plasma glucose and HbA1c levels in diabetic patients (18,22,23,24,25). These two ARBs’ beneficial effects on insulin resistance and glucose metabolism are due to their RAS blockade ability. In addition to that, it has been reported that telmisartans’ partial PPAR-gamma agonistic feature increases insulin sensitivity indepently from RAS blocade effect (17). Telmisartan is the only ARB which has PPAR-gamma stimulating effect at therapeutic dose plasma concentrations. Other ARBs and losartan do not have PPAR-gamma activity at therapeutic concentrations (17,18). In studies, significant structural similarities were found between pioglitazone (synthetic PPAR-gamma agonist) and telmisartan and telmisartan is thought to act as a synthetic PPAR-gamma ligand (18). However the molecular studies of telmisartan showed that telmisartan binds to the same ligand as full PPAR-gamma agonists, but provides 70%-75% less activation compared to these molecules (18). In addition, telmisartan has been shown to reduce diet-induced weight gain regardless of energy intake (18,26). This results from termisan’s adipocyte differentiation and its being a weak stimulus on adipogenesis (18). Telmisartan has been shown to increase fatty acid catabolism in tissues where it activates PPAR-gamma-dependent lipolytic pathways (27). This positive effect of on the body weight provided by telmisartan was absent in Losartan, therefore it has been reported that this effect was independent from the inhibition of RAS (28). In the literature, three experimental and clinical studies are available comparing metabolic activities of losartan and telmisartan. In Benson and colleagues’ study including high-carbohydrate diet taking rats, at the end of five weeks of treatment, telmisartan groups’ glucose, insulin and triglyceride levels have dropped significantly compared to losartan and control groups. Also in this study, telmisartan caused a 10% reduction in the body weight of rats compared to losartan and control group (18). In Vitale and colleagues’ study, in patients with newly diagnosed hypertension and metabolic syndrome, fasting glucose, insulin and HOMA scores dropped significantly in the telmisartan group compared to losartan (29). In Bahadir et al. study; in hypertensive patients with metabolic syndrome, telmisartan and losartan had neutral effects on insulin resistance calculated by HOMA-IR (30). Our study’s results are interestingly different from these comparing studies. This could be due to several reasons. First of all, subjects used in these studies were not diabetic and also interpretations were made through HOMA-IR calculations that were determined only with blood glucose and insulin levels. Because of insulin having a pulsatile secretion kinetic in normal physiology (31) and in routine measurements proinsulin and insulin are tested together (32), this method does not seem very useful due to the error it may cause at the determination of insulin sensitivity. Unlike this study; in our study, diabetic patients were included and insulin sensitivity was determined by HECT that is still regarded as the primary standard tool in the whole world for insülin sensitivity calculation (21). Therefore, although the results appear to be different from previous studies, our study is still reliable. Similar to Bahadir et als’ study (30), we found no significant change in fasting plasma insulin levels, fasting plasma glucose and calculated HOMA-IR values at the end of the study compared to initial vaules. However, in telmisartan to losartan switching group there was a significant improvement in terms of insulin sensitivity calculated by HECT. Accuracy and reliability of HECT results and calculation of HOMA-IR obtained from these results are indisputable. Different results obtained from this method especially reveal the importance of the method chosen for studies with a limited number of patients.

In our study, we measured serum adiponectin concentration to compare both drugs’ effects on adipocyte differentiation. At the beginning, there was no significant difference between two groups in terms of adiponectin levels. Also, in both groups, at the end of the study, we did not detect a significant change in adiponectin levels compared to initial values. In the literature, we found one study that compared losartan and telmisartans’ effect on adiponectin levels published by Erba et al. Their results were similar to ours and both drugs did not show a significant effect on adiponectin levels (17). In studies, it has been shown that an increase in adipocyte differentiation and adiponectin synthesis occurs with AT1 blockade (12). This approach may explain why there was no difference between two drugs in terms of their effect on adiponectin levels. During the study, there was no change made in patients’ nutrition, physical activity habits and antidiabetic treatment. Altough this eliminates complex results, in losartan to telmisartan switching group we observed statistically significant weight loss and BMI reduction compared to initial values (p=0.034 and p=0.023). These results are consistent with the literature (18,26). Telmisartan’s weight loss effect was not observed in losartan. Hence this effect is thought to be independent from RAS inhibition (18). Weight loss is known to enhance insulin sensitivity. Even though losartan does not provide weight loss like telmisartan, it is more effective on insulin resistance. This makes us think that losartan is more effective on insulin sensitivity than telmisartan. Our explanation of this condition is: RAS inhibition has more effect on insulin sensitiviy than partial PPAR-gamma activity and in tissues; losartan is more potent in RAS inhibition than telmisartan. For this hypothesis to be valid, more in-vitro experimental comparative studies are needed.

In conclusion, in metabolically controlled type 2 diabetic patients, telmisartan (an ARB with a partial PPAR-gamma agonist effect) has more positive effect on body weight than losartan (which do not have PPAR-gamma agonist effect) but losartan reduces insulin sensitivity more than telmisartan. We argue that considering the positive metabolic effects, losartan is an antihypertensive agent that can be used for hypertensive patients with type 2 diabetes.


1.    Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities–the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-81.
2.     Grunfeld B, Balzareti M, Romo M, Gimenez M, Gutman R. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 1994;23(Suppl 1):112-15.
3.     El-Atat FA, McFarlane SI, Sowers JR. Diabetes, Hypertension and cardiovascular derangements: Update on the pathophysiology and management . Curr Hypertens Rep 2004;23:187-98.
4.     Gress TW, Nieto FJ, Shadar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-12.
5.     Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004;286:1597-602.
6.     Fukuda N, Satoh C, Hu WY, et al. Endogenous angiotensin II suppresses insulin signaling in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 2001;19:1651-8.
7.     Isenovic ER, Meng Y, Jamali N, Milivojevic N, Sowers JR. Ang II attenuates IGF-1-stimulated Na-K-ATPase activity via PI3-K/Akt pathway in vascular smooth muscle cells. Int J Mol Med 2003;12:1-12.
8.    Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J. Effect of captopril on glucose concentration. Possible role of augmented post-prandial forearm blood flow. Diabetes Care 1990;13:1109-11.
9.     Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994;3:185-8.
10.    Haenni A, Berglund L, Reneland R, et al. The alterations in insulin sensitivity during angiotensin-converting enzyme inhibitor treatment are related to changes in the calcium/magnesium balance. Am J Hypertens 1997;10:145-51.
11.    Hoenack C, Roesen P. Inhibition of angiotensin type 1 receptor prevents decline of glucose transporter (GLUT4) in diabetic rat heart. Diabetes 1996;45:82-7.
12.    Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, Teboul M, Massiera F, Sharma AM. The adipose-tissue renin-angiotensin- aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003;35:807-25.
13.    Haenni A, Andersson PE, Lind L, Berne C, Lithell H. Electrolyte changes and metabolic effects of lisinopril/bendrofluazide treatment: results from a randomized, double-blind study with parallel groups. Am J Hypertens 1994;7:615-22.
14.    Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. A meta-analysis of randomised clinical trials. Diabetes Metab 2004;30:487-96.
15.    Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-57.
16.    Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacological Research 2005;51:85-94.
17.    Erbe DV, Gartrell K, Zhang Y, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPAR gamma by angiotensin II type 1-receptor antagonists. Vascular Pharmacology 2006;45(Suppl 3):154-62.
18.    Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz T W. Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR gamma–Modulating Activity. Hypertension 2004;43:993-1002.
19.    Pogach LM, Brietzke SA, Cowan CL Jr, et al. VA/DoD Diabetes Guideline Development Group. Development of evidence-based clinical practice guidelines for diabetes: the Department of Veterans Affairs/Department of Defense guidelines initiative. Diabetes Care 2004;27(Suppl 2):82-9.
20.    Lenfant C, Chobanian AV, Jones DW, Roccella EJ; Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 2003;41(Suppl 6):1178-9.
21.    DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237(Suppl 3):214-23.
22.    Honjo, S. Nichi, Y. Wada, Y. Hamamoto, Y. Koshiyam AH. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 2005;28:498.
23.    Nagel J, Tieetz AB, Göke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metab Clin and Experimental 2006; 55:1149-54.
24.    Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan:implications for threating insulin resistant hypertension and cardiovascular disease. Diabetes Care 2004;27:1015.
25.    Paolisso G, Tagliamonte MR, Gambardella A, et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997;11:307-12.
26.    Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator activated protein (gamma) selective modulator. Mol Endocrinol 2003;17:662-76.
27.    He H, Yang D, Ma L, et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependentpathways.Hypertension 2010;55:869-79.
28.    Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin angiotensin system. J Hypertens 2004;22:2253-61.
29.    Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology 2005;4(Suppl 6):8 .
30.    Bahadir O, Uzunlulu M, Oguz A, Bahadir MA. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 2007;30(Suppl 1):49-53.
31.    Chevenne D, Trivin F, Porquet D. Insulin assays and reference values. Diabetes Metab 1999;25:459-76.
32.    Mykkanen L, Haffner S, Hales C, Ronnemaa T, Laakso M. The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 1997;46:1990-95.